Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities

International Journal of Infectious Diseases

Volumn 56, Issue , 2017, Pages 194-199

  McAnaw, S E ^a   Hesseling, A C ^a   Seddon, J A ^a   Dooley, K E ^a   Garcia Prats, A J ^a   Kim, S ^a   Jenkins, H E ^a   Schaaf, H S ^a   Sterling, T R ^a   Horsburgh, C R ^a  

^a RESIST TB   (United States)

Author keywords

MDR tuberculosis; MDR TB Pediatric Clinical trials; Multidrug resistant tuberculosis; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

CHILDHOOD DISEASE; CLINICAL TRIAL (TOPIC); COMMUNITY INTEGRATION; HUMAN; MEDICAL RESEARCH; MULTIDRUG RESISTANT TUBERCULOSIS; REVIEW; SAMPLE SIZE; STUDY DESIGN; ADULT; CHILD; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ADULT; ANTITUBERCULAR AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 85009279019     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2016.11.423     Document Type: Review

References (32)

1. 1 Gandhi, N.R., Nunn, P., Dheda, K., Schaaf, H.S., Zignol, M., van Soolingen, D., et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375 (2010), 1830–1843.
2. 2 Marais, B.J., Gie, R.P., Schaaf, H.S., Hesseling, A.C., Obihara, C.C., Starke, J.J., et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 8 (2004), 392–402.
3. 3 Iseman, M.D., Treatment of multidrug-resistant tuberculosis. N Engl J Med 329 (1993), 784–791.
4. 4 Wallis, R.S., Maeurer, M., Mwaba, P., Chakaya, J., Rustomjee, R., Migliori, G.B., et al. Tuberculosis – advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis 16 (2016), e34–e46.
5. 5 Gler, M.T., Skripconoka, V., Sanchez-Garavito, E., Xiao, H., Cabrera-Rivero, J.L., Vargas-Vasquez, D.E., et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366 (2012), 2151–2160.
6. 6 Lee, M., Lee, J., Carroll, M.W., Choi, H., Min, S., Song, T., et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 367 (2012), 1508–1518.
7. 7 Tang, S., Yao, L., Hao, X., Liu, Y., Zeng, L., Liu, G., et al. Clofazamine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 60 (2015), 1361–1367.
8. 8 Tang, S., Yao, L., Hao, X., Zhang, X., Liu, G., Liu, X., et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 45 (2015), 161–170.
9. 9 Diacon, A.H., Pym, A., Grobusch, M.P., de los Rios, J.M., Gotuzzo, E., Vasilyeva, I., et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371 (2014), 723–732.
10. 10 DR-TB clinical trials progress report. RESIST-TB; 2016. Available at: http://www.resisttb.org/?page_id=1602.(accessed September 29, 2016).
11. 11 Perez-Velez, C.M., Marais, B.J., Tuberculosis in children. N Engl J Med 367 (2012), 348–361.
12. 12 Abubakar, I., Zignol, M., Falzon, D., Raviglione, M., Ditiu, L., Masham, S., et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 13 (2013), 529–539.
13. 13 Zignol, M., Sismanidis, C., Falzon, D., Glaziou, P., Dara, M., Floyd, K., Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J 42 (2013), 701–707.
14. 14 Jenkins, H.E., Tolman, A.W., Yuen, C.M., Parr, J.B., Keshavjee, S., Pérez-Vélez, C.M., et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet 383 (2014), 1572–1579.
15. 15 Dodd, P.J., Sismanidis, C., Seddon, J.A., Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis 16 (2016), 1193–1201.
16. 16 Ettehad, D., Schaaf, H.S., Seddon, J.A., Cooke, G.S., Ford, N., Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 449–456.
17. 17 Jenkins, H.E., Yuen, C.M., Rodriguez, C.A., Nathavitharana, R.R., McLaughlin, M.M., Donald, P., et al. Mortality among children diagnosed with tuberculosis: systematic review and meta-analysis. Lancet Infect Dis., 2016.
18. 18 Canetti, G., Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 92 (1965), 687–703.
19. 19 Prideaux, B., Via, L.E., Zimmerman, M.D., Eum, S., Sarathy, J., O'Brien, P., et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med 21 (2015), 1223–1227.
20. 20 Gumbo, T., Lenaerts, A.J., Hanna, D., Romero, K., Nuermberger, E., Nonclinical models for antituberculosis drug development: a landscape analysis. J Infect Dis 211 (2015), S83–S95.
21. 21 Kearns, G.L., Abdel-Rahman, S.M., Alander, S.W., Blowey, D.L., Leeder, J.S., Kauffman, R.E., et al. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N Engl J Med 349 (2003), 1157–1167.
22. 22 Garcia-Prats, A.J., Draper, H.R., Thee, S., Dooley, K.E., McIlleron, H.M., Seddon, J.A., et al. Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis. Antimicrob Agents Chemother 59 (2015), 6073–6079.
23. 23 Thee, S., Garcia-Prats, A.J., Draper, H.R., McIlleron, H.M., Wiesner, L., Castel, S., et al. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Clin Infect Dis 60 (2015), 549–556.
24. 24 Thee, S., Garcia-Prats, A.J., McIlleron, H.M., Wiesner, L., Castel, S., Norman, J., et al. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children. Antimicrob Agents Chemother 58 (2014), 2948–2951.
25. 25 Davies, G.R., Phillips, P.P., Jaki, T., Adaptive clinical trials in tuberculosis: applications, challenges and solutions. Int J Tuberc Lung Dis 19 (2015), 626–634.
26. 26 Bratton, D.J., Phillips, P.P., Parmar, M.K., A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis. BMC Med Res Methodol, 13, 2013, 139.
27. 27 Cellamare, M., Ventz, S., Baudin, E., Mitnick, C.D., Trippa, L., Bayesian response-adaptive trial in tuberculosis: the endTB trial. Clin Trials, 2016 pii: 1740774516665090.
28. 28 Wiseman, C.A., Mandalakas, A.M., Kirchner, H.L., Gie, R.P., Schaaf, H.S., Walters, E., et al. Novel application of NIH case definitions in a paediatric tuberculosis contact investigation study. Int J Tuberc Lung Dis 19 (2015), 446–453.
29. 29 Sterling, T.R., Fluoroquinolones for the treatment and prevention of multi-drug resistant tuberculosis. Int J Tuberc Lung Dis 20 (2016), S42–S47.
30. 30 Nuermberger, E., Evolving strategies for dose optimization of linezolid for treatment of tuberculosis. Int J Tuberc Lung Dis 20 (2016), S48–S51.
31. 31 O'Donnell, M.R., Padayatchi, N., Metcalfe, J.Z., Elucidating the role of clofazimine for the treatment of tuberculosis. Int J Tuberc Lung Dis 20 (2016), S52–S57.
32. 32 Villarino, M.E., Scott, N.A., Weis, S.E., Weiner, M., Conde, M.B., Jones, B., et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr 169 (2015), 247–255.